bluebird bio (NASDAQ:BLUE) Shares Up 11.9%

bluebird bio Inc (NASDAQ:BLUE) shot up 11.9% during trading on Tuesday . The stock traded as high as $86.09 and last traded at $85.69, 2,513,517 shares traded hands during trading. An increase of 270% from the average session volume of 678,819 shares. The stock had previously closed at $76.60.

A number of analysts have recently issued reports on BLUE shares. BidaskClub raised shares of bluebird bio from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 28th. Stifel Nicolaus set a $96.00 target price on shares of bluebird bio and gave the company a “hold” rating in a research note on Friday, November 1st. ValuEngine raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. William Blair reissued a “hold” rating on shares of bluebird bio in a research note on Tuesday. Finally, Svb Leerink raised shares of bluebird bio from a “market perform” rating to an “outperform” rating and set a $119.00 target price for the company in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $138.43.

The company has a debt-to-equity ratio of 0.12, a current ratio of 6.22 and a quick ratio of 6.22. The firm has a fifty day moving average of $79.60 and a two-hundred day moving average of $106.15. The stock has a market capitalization of $4.74 billion, a P/E ratio of -8.02 and a beta of 2.16.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($3.73) earnings per share for the quarter, missing the consensus estimate of ($3.54) by ($0.19). The firm had revenue of $8.91 million during the quarter, compared to the consensus estimate of $12.47 million. bluebird bio had a negative net margin of 1,326.56% and a negative return on equity of 42.29%. The business’s revenue was down 22.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.73) earnings per share. As a group, sell-side analysts forecast that bluebird bio Inc will post -14.06 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC raised its holdings in shares of bluebird bio by 1.6% in the second quarter. LPL Financial LLC now owns 5,373 shares of the biotechnology company’s stock valued at $683,000 after acquiring an additional 84 shares in the last quarter. Capital Investment Advisory Services LLC raised its holdings in shares of bluebird bio by 100.0% in the second quarter. Capital Investment Advisory Services LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 100 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of bluebird bio by 0.5% in the second quarter. First Light Asset Management LLC now owns 18,840 shares of the biotechnology company’s stock valued at $2,396,000 after acquiring an additional 103 shares in the last quarter. MML Investors Services LLC raised its holdings in shares of bluebird bio by 3.9% in the second quarter. MML Investors Services LLC now owns 3,812 shares of the biotechnology company’s stock valued at $485,000 after acquiring an additional 143 shares in the last quarter. Finally, Sawtooth Solutions LLC raised its holdings in bluebird bio by 12.1% in the second quarter. Sawtooth Solutions LLC now owns 1,609 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 174 shares in the last quarter.

bluebird bio Company Profile (NASDAQ:BLUE)

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

See Also: What are high-yield dividend stocks?

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.